scholarly journals Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer

Cancer ◽  
2017 ◽  
Vol 123 (13) ◽  
pp. 2535-2542 ◽  
Author(s):  
Elizabeth M. Cespedes Feliciano ◽  
Marilyn L. Kwan ◽  
Lawrence H. Kushi ◽  
Wendy Y. Chen ◽  
Erin K. Weltzien ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Body Mass ◽  
Pam50 Subtype

scholarly journals Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)

2015 ◽  
Vol 107 (9) ◽  
Author(s):  
Jennifer A. Ligibel ◽  
Constance T. Cirrincione ◽  
Minetta Liu ◽  
Marc Citron ◽  
James N. Ingle ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Body Mass ◽  
Node Positive ◽  
Pam50 Subtype ◽  
Positive Breast Cancer

Prognostic significance of body mass index in breast cancer patients with hormone receptor-positive tumours after curative surgery

2013 ◽  
Vol 36 (6) ◽  
pp. 297 ◽  
Author(s):  
Peng Xing ◽  
Ji-Guang Li ◽  
Feng Jin ◽  
Ting-Ting Zhao ◽  
Qun Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Body Mass ◽  
Hormone Receptor ◽  
Univariate Analysis ◽  
Prognostic Significance ◽  
Axillary Lymph ◽  
Nodal Stage ◽  
Hormone Receptor Positive ◽  
High Bmi

Purpose: Obesity has been recognized as a significant risk factor for postmenopausal breast cancer. The aim of this study is to investigate the prognostic significance of body mass index (BMI) in hormone receptor-positive, operable breast cancer. Methods: In this retrospective cohort study, 1,192 consecutive patients with curative resection of primary breast cancer were enrolled. Patients were assigned to two groups according to BMI: normal or underweight (BMI < 23.0 kg/m2) and overweight or obese (BMI ≥23.0 kg/m2). Associations among BMI and clinicopathological characteristics and prognosis of patients were assessed. Results: A high BMI was significantly (P < 0.01) correlated with age, nodal stage, ALNR, ER positivity, PR positivity and menopausal status at diagnosis. Univariate analysis revealed that BMI, pathologic T stage, nodal stage, axillary lymph node ratio (ALNR) and adjuvant radiotherapy history were significantly (P < 0.05) associated with disease-free survival and overall survival, irrespective of tumour hormone receptor status. Multivariate analysis revealed BMI as an independent prognostic factor in all cases and in hormone receptor-positive cases. Conclusion: A high BMI (≥23.0 kg/m^2) is independently associated with poor prognosis in hormone receptor-positive breast cancer.

scholarly journals Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance)

2021 ◽  
Author(s):  
Jennifer A Ligibel ◽  
Luke Huebner ◽  
Hope S Rugo ◽  
Harold J Burstein ◽  
Debra L Toppmeyer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Physical Activity ◽  
Body Mass Index ◽  
Metastatic Breast Cancer ◽  
Body Mass ◽  
Hormone Receptor ◽  
Metastatic Breast ◽  
Hazard Ratio ◽  
First Line ◽  
Risk Of Cancer

Abstract Background Obesity and inactivity are associated with increased risk of cancer related- and overall mortality in breast cancer, but there are few data in metastatic disease. Methods CALGB 40502 was a randomized trial of first-line taxane-based chemotherapy for patients with metastatic breast cancer. Height and weight were collected at enrollment. After 299 patients enrolled, the study was amended to assess recreational physical activity (PA) at enrollment using the Nurses’ Health Study Exercise Questionnaire. Associations with progression-free survival (PFS) and overall survival (OS) were evaluated using stratified Cox modeling (strata included hormone receptor status, prior taxane, bevacizumab use, and treatment arm). Results 799 patients were enrolled and at the time of data lock, median follow-up was 60 months. At enrollment, median age was 56.7 years, 73.1% of participants had hormone receptor-positive cancers, 42.6% had obesity, and 47.6% engaged in less than 3 metabolic equivalents of task (MET)-hours of PA/week (&lt;1 hour of moderate PA). Neither baseline body mass index nor PA was statistically significantly associated with PFS or OS, although there was a marginally statistically significant increase in PFS (hazard ratio = 0.83, 95% confidence interval [CI] = 0.79, 1.02; p = .08) and OS (hazard ratio = 0.81, 95% CI = 0.65, 1.02; p = .07) in patients who reported PA greater than 9 MET-hours/week vs 0–9 MET-hours/week. Conclusions In a trial of first-line chemotherapy for metastatic breast cancer, rates of obesity and inactivity were high. There was no statistically significant relationship between body mass index and outcomes. More information is needed regarding the relationship between PA and outcomes.

scholarly journals Effect of body mass index on pharmacokinetics of paclitaxel in patients with early breast cancer

2021 ◽  
Author(s):  
Vikram Gota ◽  
Manjunath Nookala ◽  
Avinash Bonda ◽  
Ashwin Karanam ◽  
Bharati Shriyan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Body Mass ◽  
Early Breast Cancer

scholarly journals Impact of body mass index and weight fluctuation on lymphedema risk in patients treated for breast cancer

2013 ◽  
Vol 142 (1) ◽  
pp. 59-67 ◽  
Author(s):  
Lauren S. Jammallo ◽  
Cynthia L. Miller ◽  
Marybeth Singer ◽  
Nora K. Horick ◽  
Melissa N. Skolny ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Body Mass ◽  
Weight Fluctuation
Sign in / Sign up

Export Citation Format

Share Document